Shanghai Vitalgen Biopharma Co., Ltd.

This early-stage study is testing a new gene therapy, VGN-R09b, for Parkinson's disease. It aims to see if the treatment is safe and if it can help control motor symptoms in people whose current medications aren't working well enough. The therapy is delivered via a one-time injec…

This early-stage study is testing whether a new gene therapy called VGR-R01 is safe for people with Bietti Crystalline Dystrophy, a rare genetic eye disease that causes vision loss. The trial will enroll 12 adults to receive a single injection into the eye and monitor them closel…

This study is testing whether a one-time gene therapy injection called VGR-R01 can slow or stop vision loss in adults with Bietti Crystalline Dystrophy, a rare inherited retinal disease. It will enroll 45 participants, with two-thirds receiving the therapy in one eye and the rest…